Gastroparesis due to semaglutide

Gastroparesis due to semaglutide video

The most severe side effect of drugs that have semaglutide as the active agent - Ozempic, Wegovy, and Rybelsus - is gastroparesis, the paralysis of the stomach. Gastroparesis is a severe condition in which food movement is considerably slowed down or stopped from the stomach to the small intestine in the absence of a mechanical blockage. Now that these drugs are being commonly used for weight loss, we can expect many complaints of gastroparesis to surface. If you've been diagnosed with gastroparesis after using Ozempic, Wegovy, or Rybelsus, please do not hesitate to contact our experienced attorneys, who might be able to help you file a claim.

Claim Application

Type 2 diabetes medication linked to gastroparesis

While the most common causes of gastroparesis are surgery on the esophagus, stomach, or small intestine, which may injure the vagus nerve, it was recently found that taking semiglutide, the active agent in some type 2 diabetes medication, may also cause the disorder. Semaglutide is the generic name for Ozempic, Wegovy, and Rybelsus. The drugs were developed by Novo Nordisk and approved by the FDA to treat type II diabetes, (except Wegovy, which is approved for weight loss) but many doctors prescribe them for weight loss purposes, as well.

Gastroparesis can lead to several health complications, including difficult-to-control blood sugar levels, which can worsen diabetes, severe dehydration as a result of repeated vomiting, and malnutrition because of poor absorption of nutrients.

Studies link GLP-1 and RA drugs to gastroparesis

Semaglutide Side Effects

Over the past years, the popularity of glucagon-like peptide 1 (GLP-1) receptor agonist (RA) drugs such as Ozempic has massively increased. While the drugs ability to treat diabetes and assist with weight loss has been praised on social media by influencers and celebrities, there is a great deal of concern regarding potential side effects, including a severe one, stomach paralysis. 

It is worth noting that stomach paralysis can also be a consequence of diabetes, which is the most common known cause of this condition.

In October 2023, the Journal of the American Medical Association (JAMA) examined adverse events associated with GLP-1 RA drugs used for weight loss, and published in an October edition of JAMA Network letter, where they concluded that studies had found increased risks of gastrointestinal adverse disorders, such as gastroparesis and bowel obstruction.

The study recommends that these results should be "considered by patients contemplating using the drugs for weight loss."

Another recent study published by researchers from the University of British Columbia shows that compared to bupropion-naltrexone, patients on GLP-1 agonist drugs present a three times higher risk of gastroparesis.

This is the first epidemiological study that links the drugs prescribed for type 2 diabetes and weight loss to stomach paralysis and other gastrointestinal conditions.

Also, a letter from the American Society of Anesthesiologists warns about potential adverse gastrointestinal effects such as nausea, vomiting, and delayed gastric emptying, complicating surgical procedures.

Many bariatric surgeons have called for additional studies to determine the connection between semaglutide and gastrointestinal issues such as stomach paralysis. Although the severity of the symptoms connected to gastroparesis caused by the use of semaglutide varies, common symptoms of the disorder include: 

  • Nausea and vomiting
  • Abdominal bloating and pain
  • Acid reflux
  • Fluctuations in blood sugar levels 
  • Heightened satiety

If you are experiencing any of these symptoms while taking one of these drugs - Ozempic, Wegovy, and Rybelsus - you should call your doctor right away.

Individuals diagnosed with gastroparesis sued the manufacturer

Novo Nordisk, the manufacturer of Ozempic, Wegovy, and Rybelsus, was named as a defendant in several product liability lawsuits. The first lawsuit was filed in August 2023 by a Louisiana resident who alleges that after taking Ozempic for one year, she developed severe gastrointestinal complications and was diagnosed with stomach paralysis (gastroparesis).

Although Novo Nordisk denies any wrongdoing, the plaintiff claims the drug manufacturer "failed to warn" users of the potential risks involved with the GLP-1 RA medication.

Today, law firms are investigating over 500 other inquiries from people struggling with semaglutide side effects across 45 states.

We can help you file your Ozempic/Wegovy/Rybelsus claim

Have you been diagnosed with stomach paralysis after using Ozempic, Wegovy, or Rybelsus? If yes, please do not hesitate to contact our law firm. With over three decades of experience assessing personal injury claims, our team of experts will thoroughly evaluate your case to determine whether you can file a claim and obtain rightful financial compensation from the liable manufacturer. We understand how difficult dealing with gastroparesis can be. Therefore, we will do everything possible to make the legal process as simple and fast as possible for you. We will need evidence of you taking Ozempic, Wegovy, or Rybelsus and your medical records with your gastroparesis diagnosis to initiate the legal process. After carefully assessing these documents, we will inform you if you are entitled to file a claim.